Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX neoadjuvant chemotherapy 5 cycles versus 3 cycles for locally advanced gastric adenocarcinoma
ChiCTR1900023293Phase 3Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin and tegafur in gastric adenocarcinoma (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Pathological complete response rate. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
oxaliplatintegafur
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900023293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023293.